BRIEF-Supernus Pharmaceuticals Inc Enters Asset Purchase Agreement With Navitor On April 1, 2026

Supernus Pharmaceuticals, Inc. -1.44% Post

Supernus Pharmaceuticals, Inc.

SUPN

49.22

49.22

-1.44%

0.00% Post

April 7 (Reuters) - Supernus Pharmaceuticals Inc SUPN.O:

  • SUPERNUS PHARMACEUTICALS INC - ENTERS ASSET PURCHASE AGREEMENT WITH NAVITOR ON APRIL 1, 2026 - SEC FILING

  • SUPERNUS PHARMACEUTICALS INC - TO BUY ASSETS RELATED TO NV-5138 OR SPN-820 INCLUDING IP AND INVENTORY - SEC FILING

  • SUPERNUS PHARMACEUTICALS INC - PURCHASE PRICE INCLUDES PHASE 2B STUDY AND MILESTONE PAYMENTS UP TO $350 MILLION - SEC FILING

  • SUPERNUS PHARMACEUTICALS INC - AGREEMENT INCLUDES FIVE-YEAR NON-COMPETE AND NON-SOLICITATION COVENANT - SEC FILING

Source text: [ID:n0001104659-26-040497]

Further company coverage: SUPN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.